Technology

Lab Automation Market to Reach $11.31 Billion by 2031, Driven by Rising Pharmaceutical & Biotech R&D Expenditures and Increasing Demand for Automated Laboratories and Instruments – Report by Meticulous Research®

Published

2 years ago

September 16, 2024

REDDING, Calif., Sept. 16, 2024 /PRNewswire/ — According to a new market research report titled, ‘Lab Automation Market Size, Share, Forecast, & Trends Analysis by Product (Liquid Handling, Nucleic Acid Purification System, Microplate Reader, ELISA, LIMS, ELN), Application (Drug Discovery, Diagnostics, Genomics),End User—Global Forecast to 2031.

The lab automation market is projected to reach $11.31 billion by 2031, at a CAGR of 7.3% from 2024 to 2031.

Download FREE PDF Brochure Of Lab Automation Market – https://www.meticulousresearch.com/pressrelease/967/lab-automation-market-2031

Rising pharmaceutical and biotech R&D expenditures, the increasing demand for automated laboratories and instruments, the high prevalence of chronic and infectious diseases, and initiatives supporting life sciences R&D are driving the growth of the lab automation market. However, the high costs of advanced lab automation equipment and funding & infrastructure limitations in developing countries are factors restraining the growth of this market.

Furthermore, growth in genomics & proteomics research, the increasing focus on food safety & quality, rising awareness & growing adoption of personalized medicines, and emerging economies are expected to generate growth opportunities for the players operating in the lab automation market. However, equipment maintenance & repair and data security & privacy concerns are major challenges impacting market growth.

Get Insightful Data On Regions, Market Segments, Customer Landscape, And Top Companies (Charts, Tables, Figures And More) – https://www.meticulousresearch.com/download-sample-report/cp_id=1221

Automated Laboratories: Effective Management of Clinical Workflows

Lab automation is being widely adopted in clinical laboratories to increase accuracy and efficiency and reduce costs and errors. In the field of medicine, a diagnostic error can incur very high costs. Hence, automating clinical laboratories can significantly reduce human errors and associated costs.

Automating clinical laboratories can have a positive impact on patient outcomes. Quick and reliable diagnostic results allow medical professionals to initiate appropriate treatments, improving the chances of patient survival. Additionally, limited resources, long waiting times for diagnostic results, and the shortage of skilled laboratory staff can lead to poor patient outcomes. The implementation of lab automation in clinical laboratories helps mitigate these issues and provides quick and reliable results, improving patient outcomes.

In the U.S., an estimated 10–20% of diagnoses are inaccurate and result in 40,000–80,000 deaths each year. Automation improves the ordering, testing, and reporting of diagnostic tests and ensures higher throughput, increased productivity, efficient use of reagents & materials, and standardization, decreasing errors and improving turnaround times.

Browse In-depth Report Now – https://www.meticulousresearch.com/product/lab-automation-market-1221

The players operating in this market are focused on launching new automated diagnostic instruments. For instance:

In May 2024, Abbott Laboratories (U.S.) launched its GLP Systems Track in India to support the high-volume needs of laboratories.In September 2023, Yourgene Health plc (U.K.) launched the Yourgene MagBench Automated DNA Extraction Instrument and Kit for Noninvasive Prenatal Testing (NIPT) workflows.In June 2023, Becton, Dickinson and Company (U.S.) launched its BD FACSDuet Premium Sample Preparation System for cellular diagnostic applications.In January 2023, QIAGEN N.V. (Netherlands) launched the EZ2 Connect MDx Platform for automated sample processing in diagnostic labs.In May 2022, Becton, Dickinson and Company (U.S.) launched BD COR MX, a fully automated, high-throughput infectious disease molecular diagnostics platform.

Lab Automation Market Analysis: Key Segmental Findings

By Product: In 2024, the systems segment is expected to account for the major share of 71.5% of the lab automation market. However, the software segment is expected to grow at the fastest CAGR of 7.4% during the forecast period of 2024–2031.By Application: In 2024, the drug discovery segment is expected to account for the largest share of the market. However, the clinical diagnostics segment is expected to grow at the fastest CAGR during the forecast period of 2024–2031.By End User: In 2024, the pharmaceutical & biotechnology companies’ segment is expected to account for the largest share of 41.0% of the global market.

Explore the Key Market Segments Driving Growth (Download Free Sample) – https://www.meticulousresearch.com/download-sample-report/cp_id=1221

Geographic Analysis:

North America Dominates the Global Market

North America is expected to account for the largest share of 40.8% of the lab automation market. In terms of value, in 2024, the U.S. is expected to account for the major share of 92% of the lab automation market in North America. Pharmaceutical companies in the U.S. are at the forefront of adopting cutting-edge technologies, with a strong emphasis on the implementation of lab automation systems to enhance operational efficiency and gain a competitive edge in the pharmaceutical sector. The adoption of lab automation technologies is driven by several factors, including the surging need for high-throughput analysis, increasing investments in research and development, laboratories’ growing need for increased efficiency, precision, and productivity, and the increasing focus on genomics research and genetic testing. These dynamics are boosting the adoption of lab automation across the country. The U.S. has low market barriers for developing and commercializing pharmaceuticals due to the supportive domestic environment. With the availability of government funding for research activities, robust capital markets, and strong academic research in the country, the U.S. is the world’s largest scientific research base, attracting most global venture capital investments in the biotechnology industry.

Asia-Pacific to Witness Rapid Growth

Asia-Pacific is expected to record the fastest growth over the forecast period, with the regional market reaching $2.74 billion by 2031. The high growth of this regional market is driven by the expanding pharmaceutical & biotechnology industries, rapidly improving healthcare infrastructure, growth in pharmaceutical research, and increasing government funding in APAC. The Asia-Pacific region has become one of the most attractive markets for healthcare & life sciences companies worldwide, primarily due to changing demographics and accelerated economic growth in the region. Countries such as China, India, South Korea, and Indonesia are expanding their healthcare infrastructure, driving the demand for laboratory automation.

Have specific research needs? Request a customized research report – https://www.meticulousresearch.com/request-customization/cp_id=1221

In 2024, China is expected to account for the largest share of the lab automation market in Asia-Pacific. The country’s large market share is mainly attributed to government initiatives focusing on research and development, increasing R&D expenditures of pharmaceutical and biopharmaceutical companies, favorable regulatory policies, the rising prevalence of infectious & chronic diseases, the rising geriatric population, and the increased demand for lab automation among clinical laboratories due to increased disease prevalence.

Germany Continues to Dominate the Lab Automation Market in Europe

In 2024, Germany is expected to account for the largest share of the lab automation market in Europe. Factors such as increasing government investments in the pharmaceutical industry, growing biotech & pharmaceutical R&D expenditures, rising healthcare spending, increasing sample volumes in laboratories due to the rising incidence of chronic and infectious diseases, the increased demand for precision medicines, and the rising focus on genomics research contribute to the country’s largest market share. Germany has a favorable environment for developing and producing research-intensive, high-grade products. According to German Trade & Invest, in 2021, the pharmaceutical industry in Germany invested over $9.1 billion (€7.7 billion) in research and development. Additionally, the government and funding organizations have pledged to substantially increase public & private R&D spending and researchers by 2030 as part of the country’s Sustainable Development Goals (SDG). Thus, increasing government funding for research, the wide availability of technologically advanced laboratory informatics solutions, and laboratories’ need to reduce errors, and associated costs are expected to drive the growth of the lab automation market in Germany.

Need Insights on Regional Data? Check Out Our Detailed Analysis (Download Free Sample) – https://www.meticulousresearch.com/download-sample-report/cp_id=1221

Lab Automation Market: Competition Analysis

This report offers a competitive analysis based on an extensive assessment of the leading players’ product portfolios, geographic presence, and key growth strategies adopted over the past 3–4 years. Major companies in the lab automation market have implemented various strategies to expand their product offerings and global footprints and augment their market shares. The key strategies followed by most companies in the lab automation market include product launches, product enhancements, approvals, partnerships, collaborations, agreements, acquisitions, and expansions. The key players operating in the lab automation market include Thermo Fisher Scientific, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), Revvity, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Waters Corporation (U.S.), Tecan Group Ltd. (Switzerland), F. Hoffmann-La Roche AG (Switzerland), Siemens Healthineers AG (Germany), Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), Hudson Robotics, Inc. (U.S.), and Hamilton Company (U.S.).

Learn About the Top Companies Influencing Market Dynamics (Download Free Sample) – https://www.meticulousresearch.com/download-sample-report/cp_id=1221

Lab Automation Industry Overview: Latest Developments from Key Industry Players

In July 2024, INPECO SA (Switzerland) launched FlexLab X, a next-generation total lab automation system (TLA), at the Annual Scientific Meeting of the Association for Diagnostics & Laboratory Medicine (ADLM 2024). This system can combine analyzers from different vendors, enable space-saving layouts, offers a sleek graphical user interface, and streamlines workflows.In February 2024, Carbon, Inc. (U.S.) launched its Automatic Operation (AO) suite of solutions designed to meet the needs of dental labs, setting new standards in lab automation.In September 2023, Bio-Rad Laboratories, Inc. launched the PTC Tempo 48/48 and PTC Tempo 384 thermal cyclers that are designed to aid PCR applications such as sequencing, cloning, and genotyping.In August 2023, F. Hoffmann-La Roche Ltd launched the Cobas Connection Modules (CCM) sample conveyor systems to enable flexibility in laboratory designs.In July 2023, Agilent Technologies, Inc. launched the BioTek Gen6 Software, which is used for all BioTek detection instruments. This software also provides an intuitive user interface that offers complete control of BioTek microplate readers for absorbance, fluorescence, and luminescence measurements for endpoint and kinetic assays.In July 2023, Thermo Fisher Scientific, Inc. launched the Diomni Enterprise Software, which provides a digital platform to support testing workflows in order to accommodate rapidly evolving needs.In July 2023, Bio-Rad Laboratories launched the IH-500TM NEXT System, a fully automated system for use with Bio-Rad’s ID Cards for routine testing and specialized testing such as newborn screening.In February 2023, Revvity, Inc. launched the EnVision Nexus Multimode Microplate Reader, which provides high-throughput screening and accelerates drug discovery results.In February 2023, Beckman Coulter Life Sciences collaborated with Sciex (U.S.) to provide comprehensive workflows for high-throughput screening HT-ADME and synthetic biology studies. The Echo MS System, which is based on Sciex’s Acoustic Ejection Mass Spectrometry technology, is now compatible with Beckman’s Echo Liquid Handlers.In February 2023, Tecan Group Ltd. collaborated with Element Biosciences, Inc. (U.S.) to offer a true benchtop NGS workflow with the MagicPrep NGS and AVITI System. This collaboration was aimed at enabling the direct conversion of NGS libraries without affecting sample quality.In June 2022, Beckman Coulter Life Sciences launched the Biomek NGeniuS liquid handling system to automate the labor-intensive process of manual library construction and reagent transfers. The system also eliminates loading errors.In April 2022, Revvity, Inc. collaborated with Scitara Corporation (U.S.) to integrate PerkinElmer’s Signals Research Suite informatics platform and Scitara’s iPaaS universal connectivity solution to facilitate fully connected laboratories along with standard data integrity, data mobility, system flexibility, and user reconfigurability.

The report provides a competitive dashboard summarizing the market positioning of the 20 profiled market players in four quadrants, namely Industry Leaders, Differentiators, Emerging Companies, and Vanguards. These companies are positioned based on various parameters, including revenue, depth of offerings, brand equity, geographic presence, innovation, and organic & inorganic growth strategies. Thermo Fisher Scientific, Inc. (U.S), Danaher Corporation (U.S.), F. Hoffmann-La Roche AG (Switzerland), Hamilton Company (U.S.), Abbott Laboratories (U.S.), and Siemens Healthineers AG (Germany) are positioned in the industry leaders quadrant.

IMMEDIATE DELIVERY AVAILABLE | BUY THIS RESEARCH REPORT (Insights, Charts, Tables, Figures and More)- https://www.meticulousresearch.com/Checkout/13937383

Scope of the Report:

Lab Automation Market Assessment–by Product

SystemsAutomated Liquid Handling SystemsAutomated Nucleic Acid Purification SystemsAutomated ELISA SystemsAutomated Microplate ReadersAutomated Storage & Retrieval SystemsOther Lab Automation SystemsSoftwareLaboratory Information Management Systems (LIMS)Electronic Lab Notebook (ELN)Workstation/Equipment Automation SoftwareScientific Data Management Systems (SDMS)

Lab Automation Market Assessment–by Application

Drug DiscoveryClinical DiagnosticsGenomics & Proteomics ResearchOther Applications

(Note: Other applications include bioprocessing in biotechnology, cell analysis, basic research, forensic analysis, and quality control in the F&B industry.)

Lab Automation Market Assessment–by End User

Pharmaceutical & Biotechnology CompaniesHospitals & Diagnostic LaboratoriesAcademic & Research InstitutesOther End Users

(Note: Other end users include the food & agriculture industries, forensic laboratories, blood banks, and environmental & quality testing laboratories.)

Lab Automation Market Assessment–by Geography

North AmericaU.S.CanadaEuropeGermanyU.K.FranceItalySpainRest of Europe (RoE)Asia-Pacific (APAC)ChinaJapanIndiaRest of APAC (RoAPAC)Latin AmericaMiddle East & Africa

Browse More Related Reports:

Lab Automation Market is projected to hit $11.31 billion by 2031, growing at CAGR of 7.3% from 2024. Discover trends and growth factors driving this sector. – https://www.meticulousresearch.com/product/lab-automation-market-1221

Clinical Lab Automation Market is expected to reach $4.01 billion by 2031, at a CAGR of 7.8% from 2024 to 2031. – https://www.meticulousresearch.com/product/clinical-lab-automation-market-5762

Electronic Lab Notebook Market is expected to grow at a CAGR of 7.1% to reach $787.7 million by 2029. – https://www.meticulousresearch.com/product/electronic-lab-notebook-eln-market-4341

NGS Automation Market is expected to grow at a CAGR of 13.4% from 2022–2029 to reach $1.33 billion by 2029. – https://www.meticulousresearch.com/product/ngs-automation-market-5271

Explore future of Industrial Automation Software Market, projected to hit $59.5 billion by 2029. – https://www.meticulousresearch.com/product/industrial-automation-software-market-5279

Pharmaceutical Automation Market, valued at $11.16 Bn in 2023, is projected to reach $25.11 Bn by 2031, growing at a 10.8% CAGR from $12.21 Bn in 2024. – https://www.meticulousresearch.com/product/pharmaceutical-automation-market-5280

Lab-grown Meat Market is projected to reach $1.99 billion by 2035, at a CAGR of 21.4% during forecast period of 2025–2035. – https://www.meticulousresearch.com/product/lab-grown-meat-market-5293

North America Electronic Lab Notebooks Market is projected to reach $372.7 million by 2030, at a CAGR of 6.8% from 2024 to 2030. – https://www.meticulousresearch.com/product/north-america-electronic-lab-notebook-market-5604

Europe Electronic Lab Notebook (ELN) Market is projected to reach $264.3 million by 2030, at a CAGR of 7% from 2024 to 2030. – https://www.meticulousresearch.com/product/europe-electronic-lab-notebook-market-5683

Pharmacy Automation Market is expected to reach $7.87 billion by 2030, at a CAGR of 7.6% during forecast period 2024–2030. – https://www.meticulousresearch.com/product/pharmacy-automation-market-5700

Life science equipment market is projected to reach $97.96 billion by 2031, at a CAGR of 6.3% from 2024 to 2031 – https://www.meticulousresearch.com/product/life-science-equipment-market-3937

Europe NGS automation Market to be worth $380.4 million by 2030, growing at a 13.4% CAGR from 2024 to 2030. – https://www.meticulousresearch.com/product/europe-ngs-automation-market-5644

North America NGS Automation Market is expected to reach $776.1 million by 2030, at a CAGR of 14% during forecast period 2024–2030 – https://www.meticulousresearch.com/product/north-america-ngs-automation-market-5736

Asia-Pacific NGS Automation Market is expected to reach $371 million by 2031 at a CAGR of 16.3% from 2024 to 2031 – https://www.meticulousresearch.com/product/asia-pacific-ngs-automation-market-5790

Lab Automation Market Research Summary

Particular

Details

Page No

244

Format

PDF

Forecast Period

2024-2031

Base Year

2023

CAGR

7.30 %

Market Size (Value)

$11.31 billion

Market Size (Volume)

Countries Covered

North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, RoE), Asia-Pacific (China, Japan, India, RoAPAC), Latin America, and the Middle East & Africa.

Key Companies

Thermo Fisher Scientific, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), Revvity, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Waters Corporation (U.S.), Tecan Group Ltd. (Switzerland), F. Hoffmann-La Roche AG (Switzerland), Siemens Healthineers AG (Germany), Abbott Laboratories (U.S.), Becton, Dickinson, and Company (U.S.), Hudson Robotics, Inc. (U.S.), Hamilton Company (U.S.)

Click here to: Get Free Sample Pages of this Report

Hot Industry Reports: Emerging Trends and Market Forecasts

Veterinary Practice Management Software Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/veterinary-practice-management-software-market-1432

Asia Pacific Orthodontics Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/asia-pacific-orthodontics-market-4978

Feed Software Market by Size, Share, Forecast, & Trends Analysis – https://www.meticulousresearch.com/product/feed-software-market-2639

Point-of-care Diagnostics Market Size & Trends Analysis 2030 – https://www.meticulousresearch.com/product/point-of-care-diagnostics-market-4871

Soluble Dietary Fibers Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/soluble-dietary-fibers-market-3953

Genomics Market: Size, Trends & Global Forecast to 2031 – https://www.meticulousresearch.com/product/genomics-market-1262

Healthcare Gamification Market Size, Share, & Growth 2030 – https://www.meticulousresearch.com/product/healthcare-gamification-market-2592

3D Cell Culture Market Size & Growth Insights 2024-2030 – https://www.meticulousresearch.com/product/3d-cell-culture-market-1246

South East Asia Collagen Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/south-east-asia-collagen-market-3634

Next Generation Sequencing Informatics (NGS) Market Size, Share, Forecast, & Trends Analysis – https://www.meticulousresearch.com/product/ngs-informatics-market-3483

Recombinant Coagulation Factors Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/recombinant-coagulation-factors-market-1254

Crop Protection Chemicals Market Size, Share, Report, & Trends 2031 – https://www.meticulousresearch.com/product/crop-protection-chemicals-market-2584

Integrated Pest Management (IPM) Pheromones Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/integrated-pest-management-pheromones-market-5211

Sports Medicine Market: Size, Share, Forecast & Trends – https://www.meticulousresearch.com/product/sports-medicine-market-1215

MRI Infrastructure Capacity Assessment by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/mri-infrastructure-capacity-assessment-1217

Digital X-ray Systems Market Size, Share, Forecast, & Trends – https://www.meticulousresearch.com/product/digital-x-ray-systems-market-1183

Sports Technology Market Size, Trends & Forecast to 2030 – https://www.meticulousresearch.com/product/sports-technology-market-5584

Home Healthcare Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/home-healthcare-market-1280

Next Generation Sequencing Market Size, Share & Trends 2023-2030 – https://www.meticulousresearch.com/product/next-generation-sequencing-market-5040

Cloud Analytics Market Insights: Size, Share & Trends – https://www.meticulousresearch.com/product/cloud-analytics-market-5208

Home Medical Equipment Market by Size, Share, Forecast, & Trends Analysis – https://www.meticulousresearch.com/product/home-medical-equipment-market-1284

IoT in Healthcare Market Size, Share, & Trends 2031 – https://www.meticulousresearch.com/product/iot-in-healthcare-market-4945

Surgical Sutures Market by Size, Share, & Trends 2030 – https://www.meticulousresearch.com/product/surgical-sutures-market-4947

Lab Automation Market: Share, Trends & Forecast Analysis – https://www.meticulousresearch.com/product/lab-automation-market-1221

Asia Pacific EV Battery Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/asia-pacific-ev-battery-market-5217

Medical Imaging Market: Products, Applications, & Forecasts – https://www.meticulousresearch.com/product/medical-imaging-market-4950

Medical Ceramics Market by Size, Share, Forecast, & Trends Analysis – https://www.meticulousresearch.com/product/medical-ceramics-market-5538

Pharmaceutical Packaging Market Size, & Trends 2031 – https://www.meticulousresearch.com/product/pharmaceutical-packaging-market-5298

Ultrasound Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/ultrasound-market-4972

Tissue Diagnostics Market Insights: Size, Trends & Forecast – https://www.meticulousresearch.com/product/tissue-diagnostics-market-4971

Contact:
Mr. Khushal Bombe
Meticulous Market Research Inc.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe: +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Meticulousblog.org | Top Market Research Reports Blog – https://meticulousblog.org/
Content Source: https://www.meticulousresearch.com/pressrelease/967/lab-automation-market

Photo: https://mma.prnewswire.com/media/2506511/Lab_Automation_Market.jpg
Logo: https://mma.prnewswire.com/media/1757980/Meticulous_Research_Logo_1.jpg

View original content:https://www.prnewswire.co.uk/news-releases/lab-automation-market-to-reach-11-31-billion-by-2031–driven-by-rising-pharmaceutical–biotech-rd-expenditures-and-increasing-demand-for-automated-laboratories-and-instruments—report-by-meticulous-research-302249256.html

Technology

Ceva, Inc. Announces First Quarter 2026 Financial Results

Published

1 hour ago

May 11, 2026

Highlights strong licensing growth driven by integrated solutions and accelerating edge AI adoption

ROCKVILLE, Md., May 11, 2026 /PRNewswire/ — Ceva, Inc. (NASDAQ: CEVA), the leading licensor of silicon and software IP for the Smart Edge, today announced its financial results for the first quarter ended March 31, 2026.

First Quarter Highlights: *

Delivered total revenues of $27.0 million, up 11% year-over-yearLicensing and related revenues of $17.8 million, up 18% year-over-year and the highest in three yearsRoyalty revenues of $9.2 million, with smart edge royalties up 8% year-over-year, driven by record shipments in Wi-Fi, and strong contribution from cellular IoT, 5G infrastructure and automotive AISigned 14 IP licensing agreements, including several multi-technology engagements with existing customersSecured a major customer win for Bluetooth High Data Throughput (HDT) solution, including Ceva’s internally developed RF technology, demonstrating its system-level connectivity strategyExpanded customer engagements in 5G NTN and Ultra-Wideband, increasing value per designAI represented more than 20% of licensing and related revenues, with strong growth and key production milestones, including the Renesas R-Car V4H platform entering the 2026 Toyota RAV4, alongside a collaboration with NXP for its latest software-defined vehicle processors

*Unless otherwise stated, all comparisons are to first quarter 2025.

Amir Panush, Chief Executive Officer of Ceva, commented, “We delivered a strong start to 2026, highlighted by our highest licensing and related revenues in three years and continued momentum across our connectivity and AI portfolios. Importantly, this quarter reflects the successful execution of our strategy to expand beyond discrete IP into more integrated, system-level solutions. A major Bluetooth HDT licensing agreement, including RF, alongside our expansion in 5G NTN and Ultra-Wideband, demonstrates how we are increasing our value per design and deepening customer engagement. We also saw encouraging trends in royalties, with continued strength across our smart edge markets, partially offset by softness in smartphones.”

“In AI, our growth strategy and relentless focus on market-leading innovation are translating into production, with our technology integrated into leading automotive platforms and entering mass-volume production. With AI contributing over 20% of licensing and related revenues and a strong pipeline of engagements, we believe we are well positioned as the industry accelerates toward hybrid AI and the expansion of Physical AI at the edge.”

Business and Market Highlights
During the first quarter, Ceva signed 14 IP licensing agreements across connectivity, AI, and satellite communications, including several multi-technology engagements aligned with its strategy to deliver more integrated, system-level solutions.

The company secured a major full-stack Bluetooth HDT solution license, marking a key milestone in expanding value per design and increasing royalty contribution, while helping customers reduce integration complexity and accelerate time-to-market. Additional wins included a Wi-Fi 7 design targeting consumer IoT, a Wi-Fi 6 / Bluetooth combo engagement with a leading edge-AI SoC platform provider, and multiple Bluetooth and Wi-Fi agreements.

Ceva also expanded into new connectivity domains, introducing its PentaG-NTN platform and progressing a satellite customer engagement to a more integrated baseband solution. In Ultra-Wideband, the company launched its next-generation platform and secured a new customer as adoption accelerates across industrial and automotive applications.

In AI, Ceva continued to expand its footprint with multiple licensing agreements and achieved a key production milestone, with its AI DSP and accelerator deployed in the Renesas R-Car V4H platform, now entering production in the 2026 Toyota RAV4. The company also announced a collaboration with NXP for its latest software-defined vehicle processors. AI represented more than 20% of licensing and related revenues in the quarter, reflecting strong growth and increasing contribution.

Across its markets, Ceva continues to see strong demand in IoT and AI-driven applications, with record Wi-Fi shipments and significant growth in cellular IoT. These trends, together with the shift toward more integrated, system-level solutions and increasing adoption of Bluetooth and Wi-Fi combo chips, are driving higher value per device and reinforcing the company’s long-term royalty growth model.

Other first quarter financial data: *

GAAP gross margin was 86%, in line with last yearGAAP operating loss was $5.1 million, as compared to a GAAP operating loss of $4.4 millionGAAP net loss was $4.5 million, as compared to a GAAP net loss of $3.3 millionGAAP diluted loss per share was $0.16, as compared to GAAP diluted loss per share of $0.14Non-GAAP gross margin was 87%, in line with last yearNon-GAAP operating income was $0.5 million, as compared to non-GAAP operating income of $0.3 millionNon-GAAP net income and non-GAAP diluted earnings per share were $1.1 million and $0.04, respectively, compared with non-GAAP net income and non-GAAP diluted earnings per share of $1.4 million and $0.06, respectively

*Unless otherwise stated, all comparisons are to first quarter 2025.

Yaniv Arieli, Chief Financial Officer of Ceva, added, “Our first quarter results reflect strong licensing execution and the continued progression toward higher-value, multi-technology engagements. This shift is driving improved economics per deal and strengthening the long-term royalty potential of our business. We also continue to see encouraging trends across our diversified end markets, particularly in IoT and AI-driven applications. We continue to manage the impact of a weaker U.S. dollar and are implementing measures to partially offset the resulting expenses.”

Ceva Conference Call
On May 11, 2026, Ceva management will conduct a conference call at 8:30 a.m. Eastern Time to discuss the operating performance for the quarter.

The conference call will be available via the following dial in numbers:

U.S. Participants: Dial 1-844-435-0316 (Access Code: Ceva)International Participants: Dial +1-412-317-6365 (Access Code: Ceva)

The conference call will also be available live via webcast at the following link: https://app.webinar.net/N8PRLk4oljM. https://app.webinar.net/ePpLk12BRaD https://app.webinar.net/GvAklQElMmjPlease go to the web site at least fifteen minutes prior to the call to register.

For those who cannot access the live broadcast, a replay will be available by dialing +1 855-669-9658 or +1 412-317-0088 (access code: 4033535) from one hour after the end of the call until 9:00 a.m. (Eastern Time) on May 18, 2026. The replay will also be available at Ceva’s web site at www.ceva-ip.com.

Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties, as well as assumptions that if they materialize or prove incorrect, could cause the results of Ceva to differ materially from those expressed or implied by such forward-looking statements and assumptions. Forward-looking statements include statements about Ceva’s positioning for future growth and to serve as a foundational technology provider for intelligent, connected devices, licensing agreement wins, future industry demand, our market position for the future and future growth in the demand of our products, our forecast of financial measures for the following quarter and 2026, our long term targets and underlying assumptions, our future investments, expectations about future market, the success of our strategies and agreements, visibility into future revenue streams, and Ceva’s focus on expense management and profitability improvement. The risks, uncertainties and assumptions that could cause differing Ceva results include: the effect of intense industry competition; the ability of Ceva’s technologies and products incorporating Ceva’s technologies to achieve market acceptance; Ceva’s ability to meet changing needs of end-users and evolving market demands; the lengthy sales cycle for IP and related solutions; Ceva’s ability to diversify royalty streams and license revenues; geopolitical risks and instability, including the impact of tariffs and other trade measures and potential disruptions related to ongoing conflicts in the Middle East; and general market conditions and other risks relating to Ceva’s business and industry, including, but not limited to, those that are described from time to time in our SEC filings. Ceva assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

About Ceva, Inc.
Ceva powers the Smart Edge, bridging the digital and physical worlds to bring AI-driven products to life. Our Ceva AI fabric portfolio of silicon and software IP enables devices to Connect, Sense, and Infer – the essential capabilities for the intelligent edge. From 5G, cellular IoT, Bluetooth, Wi-Fi, and UWB connectivity to scalable Edge AI NPUs, AI DSPs, sensor fusion processors and embedded software, Ceva provides the foundational IP for devices that connect, understand their environment, and act in real time.

With more than 21 billion devices shipped and trusted by 400+ customers worldwide, Ceva is the backbone of today’s most advanced smart edge products – from AI-infused wearables and IoT devices to autonomous vehicles and 5G infrastructure. Our differentiated solutions deliver seamless integration into existing design flows, total flexibility to combine solutions based on design needs and ultra–low–power performance in minimal silicon footprint, helping customers accelerate development, reduce risk, and bring innovative products to market faster. As technology evolves toward Physical AI, Ceva’s IP portfolio lays the foundation for systems that are always connected, contextually aware, and capable of intelligent, real-time decision-making.

Visit us at www.ceva-ip.com and follow us on LinkedIn, X, YouTube, Facebook, and Instagram.

CEVA, INC. AND ITS SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF LOSS – U.S. GAAP

U.S. dollars in thousands, except per share data

Three months ended

March 31,

2026

2025

Unaudited

Revenues:

Licensing and related revenues

$ 17,820

$ 15,042

Royalties

9,204

9,203

Total revenues

27,024

24,245

Cost of revenues

3,729

3,487

Gross profit

23,295

20,758

Operating expenses:

Research and development, net

19,837

17,609

Sales and marketing

3,766

3,449

General and administrative

4,660

3,933

Amortization of intangible assets

117

149

Total operating expenses

28,380

25,140

Operating loss

(5,085)

(4,382)

Financial income, net

1,877

2,100

Remeasurement of marketable equity securities

(54)

Loss before taxes on income

(3,144)

(2,336)

Income tax expense

1,315

991

Net loss

$ (4,459)

$ (3,327)

Basic and diluted net loss per share

$ (0.16)

$ (0.14)

Weighted-average shares used to compute net loss

per share (in thousands):

Basic and diluted

27,678

23,764

Unaudited Reconciliation of GAAP to Non-GAAP Financial Measures

U.S. dollars in thousands, except per share data

Three months ended

March 31,

2026

2025

Unaudited

GAAP net loss

$ (4,459)

$ (3,327)

Equity-based compensation expense included in cost of

revenues

182

159

Equity-based compensation expense included in research

and development expenses

2,863

2,466

Equity-based compensation expense included in sales

and marketing expenses

717

566

Equity-based compensation expense included in general

and administrative expenses

1,610

1,132

Amortization of intangible assets related to acquisition of

businesses

176

208

Costs associated with asset acquisition

144

Loss (income) associated with the remeasurement of

marketable equity securities

(64)

Non-GAAP net income

$ 1,086

$ 1,402

GAAP weighted-average number of Common Stock

used in computation of diluted net loss per share (in

thousands)

27,678

23,764

Weighted-average number of shares related to

outstanding stock-based awards (in thousands)

1,810

1,618

Weighted-average number of Common Stock used

in computation of diluted earnings per share, excluding the

above (in thousands)

29,488

25,382

GAAP diluted loss per share

$ (0.16)

$ (0.14)

Equity-based compensation expense

$ 0.19

$ 0.18

Amortization of intangible assets related to acquisition

of businesses

$ 0.01

Costs associated with asset acquisition

$ 0.00

$ 0.01

Non-GAAP diluted earnings per share

$ 0.04

$ 0.06

Three months ended

March 31,

2026

2025

Unaudited

GAAP operating loss

$ (5,085)

$ (4,382)

Equity-based compensation expense included in

cost of revenues

182

159

Equity-based compensation expense included in

research and development expenses

2,863

2,466

Equity-based compensation expense included in

sales and marketing expenses

717

566

Equity-based compensation expense included in

general and administrative expenses

1,610

1,132

Amortization of intangible assets related to acquisition

of businesses

176

208

Costs associated with asset acquisition

144

Total non-GAAP operating income

$ 524

$ 293

Three months ended

March 31,

2026

2025

Unaudited

GAAP gross profit

$ 23,295

$ 20,758

GAAP gross margin

86 %

Equity-based compensation expense included in

cost of revenues

182

159

Amortization of intangible assets related to acquisition

of businesses

Total non-GAAP gross profit

23,536

20,976

Non-GAAP gross margin

87 %

Three months ended

March 31,

2026

2025

Unaudited

GAAP operating expenses

28,380

25,140

Equity-based compensation expense included in

research and development expenses

(2,863)

(2,466)

Equity-based compensation expense included in

sales and marketing expenses

(717)

(566)

Equity-based compensation expense included in

general and administrative expenses

(1,610)

(1,132)

Amortization of intangible assets related to acquisition

of businesses

(117)

(149)

Costs associated with asset acquisition

(61)

(144)

Total non-GAAP operating expenses

$ 23,012

$ 20,683

CEVA, INC. AND ITS SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS

(U.S. dollars in thousands)

March 31,

December 31,

2026

2025 (*)

Unaudited

ASSETS

Current assets:

Cash and cash equivalents

$ 21,367

$ 40,586

Marketable securities and short-term bank deposits

194,326

181,397

Trade receivables, net

17,737

19,495

Unbilled receivables

31,135

29,860

Prepaid expenses and other current assets

16,297

13,498

Total current assets

280,862

284,836

Long-term assets:

Severance pay fund

7,225

7,530

Deferred tax assets, net

274

257

Property and equipment, net

9,010

7,054

Operating lease right-of-use assets

17,190

17,486

Investment in marketable equity securities

119

Goodwill

58,308

Intangible assets, net

868

1,044

Other long-term assets

14,370

11,686

Total assets

$ 388,226

$ 388,256

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Trade payables

$ 2,388

$ 2,418

Deferred revenues

2,968

3,496

Accrued expenses and other payables

19,224

21,026

Operating lease liabilities

2,794

1,743

Total current liabilities

27,374

28,683

Long-term liabilities:

Accrued severance pay

7,428

7,690

Operating lease liabilities

14,083

14,388

Other accrued liabilities

1,158

1,037

Total liabilities

50,043

51,798

Stockholders’ equity:

Common stock

Additional paid in-capital

343,298

337,966

Treasury stock

(1,591)

Accumulated other comprehensive income (loss)

(660)

Accumulated deficit

(4,483)

(24)

Total stockholders’ equity

338,183

336,458

Total liabilities and stockholders’ equity

$ 388,226

$ 388,256

(*) Derived from audited financial statements.

The Company believes that the presentation of non-GAAP measures in the press release is useful to investors in analyzing the results for the quarters ended March 31, 2026, and 2025 because the exclusion of the applicable expenses may provide a meaningful analysis of the Company’s core operating results and comparison of quarterly results. Further, the Company believes it is useful for investors to understand how the expenses associated with the application of FASB ASC No. 718 are reflected in its statements of income. The reconciliation of financial measures should be reviewed in addition to and in conjunction with results presented in accordance with GAAP and are intended to provide additional insight into the Company’s operations that, when viewed with its GAAP results and the accompanying reconciliation, offer a more complete understanding of factors and trends affecting the Company’s business. The reconciliation of financial measures should not be viewed as a substitute for the Company’s reported GAAP results.

A reconciliation of non-GAAP guidance to the corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of expenses that may be incurred in the future, although it is important to note that these factors could be material to the Company’s results computed in accordance with GAAP.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ceva-inc-announces-first-quarter-2026-financial-results-302767706.html

SOURCE Ceva, Inc.

Technology

Screendragon Launches AI Hub, Enabling Marketing Teams and Agencies to Build and Run AI Agents Inside Real Workflows

Published

1 hour ago

May 11, 2026

CORK, Ireland, May 11, 2026 /PRNewswire/ — Screendragon today announced the launch of AI Hub, a new capability within its Agentic Marketing Orchestration platform that enables enterprise marketing teams and agencies to build, deploy and govern their own AI agents directly inside live workflows.

As AI adoption accelerates, teams are struggling to use it properly. AI Hub addresses this by enabling organisations to build their own AI agents and run them inside the workflows that already power their business, so they can harness AI at scale without losing control.

“The market is shifting from selling AI access to controlling AI execution,” said John Briggs, CEO of Screendragon. “Teams have access to AI, but no control over how it runs across the business. AI Hub changes that. It puts AI inside workflows, with the guardrails needed to scale it properly.”

Put AI Where the Work Is

AI Hub is designed to move teams beyond experimentation and into real execution.

Teams can solve their specific problems by building AI agents that:

Plug directly into live workflows Automate real marketing and creative work Keep outputs consistent, compliant and on-brand Control which models are used, and when

From briefing and content creation to approvals and compliance checks, AI becomes part of the process. Not another tab open on someone’s laptop.

Part of a Broader AI System

AI Hub is part of a wider AI offering that runs across the Screendragon platform.

Screendragon brings workflows, people, data and AI into one system, so work runs properly. AI Hub builds on that, giving teams the ability to design and run their own AI agents inside those workflows.

The wider AI offering includes:

Embedded AI Agents – Pre-built agents that automate common tasks inside workflows AI Hub – A flexible environment to build and manage your own agents AI Studio – Advanced tools for designing and optimising AI agents AI Foundry – Expert support to build and scale bespoke AI-driven workflows

Together, this gives teams a clear path. Start with what works out of the box. Then evolve towards fully customised, enterprise-grade AI execution.

Scale AI Without Losing Control of Cost

AI usage grows fast. Costs can grow faster.

AI Hub gives teams control over both:

Route work across AI models based on cost, speed and performance Use open-source models where it makes sense Avoid getting locked into one AI model

So teams can scale AI with confidence, not surprises.

From Experimentation to Execution

Most teams are still experimenting with AI. A few are starting to rely on it.

Very few are running it properly across workflows. That is the gap AI Hub is built to close.

“We were using AI in pockets, but it wasn’t scalable,” said Anne Cogan, CMO, Screendragon. “Now it is built into how we work, improving speed while maintaining full control and compliance.”

Availability

AI Hub is available immediately to all Screendragon customers, enabling them to build and deploy custom AI agents tailored to their workflows and use cases.

Find out more here

About Screendragon

Most marketing and agency teams do not struggle because of bad ideas. They struggle because the system around the work is broken.

Screendragon fixes that.

Screendragon is an Agentic Marketing Orchestration platform that enables enterprise teams and agencies to plan, resource and deliver marketing work with full visibility and control.

It connects workflows, people, data and AI into a single governed system so work runs properly, and AI actually helps instead of getting in the way.

Photo – https://mma.prnewswire.com/media/2975877/Screendragon.jpg
Logo – https://mma.prnewswire.com/media/2792757/5960921/Screendragon_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/screendragon-launches-ai-hub-enabling-marketing-teams-and-agencies-to-build-and-run-ai-agents-inside-real-workflows-302767353.html

Technology

BCE to participate in the TD Cowen 28th Annual Telecom & Media Conference

Published

1 hour ago

May 11, 2026

MONTRÉAL, May 11, 2026 /CNW/ – Curtis Millen, Executive Vice President and Chief Financial Officer of BCE Inc. (TSX: BCE) (NYSE: BCE) will participate in a fireside chat at the TD Cowen 28th Annual Telecom & Media Conference in Toronto on Thursday, May 14th, 2026, at 10:30 am eastern.

A live webcast will be available on BCE’s website.

About BCE

BCE is Canada’s largest communications company1, leading the way in advanced fibre and wireless networks, enterprise services and digital media. By delivering next-generation technology that leverages cloud-based and AI-driven solutions, we’re keeping customers connected, informed and entertained while enabling businesses to compete on the world stage. To learn more, please visit Bell.ca or BCE.ca.

____________________________

1 Based on total revenue and total combined customer connections.

Media inquiries:
Ellen Murphy
media@bell.ca

Investor inquiries:
Krishna Somers
krishna.somers@bell.ca

View original content:https://www.prnewswire.com/news-releases/bce-to-participate-in-the-td-cowen-28th-annual-telecom–media-conference-302767397.html

SOURCE BCE Inc.